Clinical Review of Nonalcoholic Steatohepatitis in Liver Surgery and Transplantation

Journal of the American College of Surgeons

Volumn 210, Issue 4, 2010, Pages 515-526

  Tevar, Amit D ^a   Clarke, Calissia ^a   Wang, Jiang ^a   Rudich, Steven M ^a   Woodle, E Steve ^a   Lentsch, Alex B ^a   Edwards, Michael L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLANGITIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ECHOGRAPHY; ELASTOGRAPHY; GASTROINTESTINAL HEMORRHAGE; HEPATITIS; HERNIA; HISTOPATHOLOGY; HISTORY; HUMAN; INFECTIOUS DIARRHEA; INTESTINE OBSTRUCTION; KIDNEY DISEASE; LIPID STORAGE; LIVER ABSCESS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER RESECTION; LIVER SURGERY; LIVER TRANSPLANTATION; LIVING DONOR; LUNG COMPLICATION; MORBIDITY; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PANCREATITIS; PARALYTIC ILEUS; PATHOPHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; ROUX Y ANASTOMOSIS; SEROMA; STEATOSIS; STOMACH BYPASS; SURGICAL MORTALITY; THROMBOSIS; WOUND COMPLICATION;

BARIATRIC SURGERY; CADAVER; DISEASE PROGRESSION; FATTY LIVER; FIBROSIS; HEPATECTOMY; HUMANS; HYPERINSULINISM; INCIDENCE; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; NECROSIS; OBESITY; TRIGLYCERIDES;

EID: 77949891998     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2010.01.020     Document Type: Review

References (114)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Schaffner F., and Thaler H. Nonalcoholic fatty liver disease. [review]. Prog Liver Dis 8 (1986) 283-298
3. Ludwig J., Viggiano T.R., McGill D.B., et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. [see comment]. Mayo Clin Proc 55 (1980) 434-438
4. Diehl A.M., Goodman Z., and Ishak K.G. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95 (1988) 1056-1062
5. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
6. Diehl A.M., Li Z.P., Lin H.Z., et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54 (2005) 303-306
7. Tilg H., and Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343 (2000) 1467-1476
8. Garcia-Monzon C., Martin-Perez E., Iacono O.L., et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33 (2000) 716-724
9. Dixon J.B., Bhathal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001) 91-100
10. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 (2002) 373-379
11. Diehl A.M., Clarke J., and Brancati F. Insulin resistance syndrome and nonalcoholic fatty liver disease. Endocr Pract 9 Suppl 2 (2003) 93-96
12. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
13. Shoelson S.E., Herrero L., and Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 132 (2007) 2169-2180
14. Shoelson S.E., Lee J., and Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 116 (2006) 1793-1801
15. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 115 (2005) 1111-1119
16. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. [review]. Hepatology 43 Suppl 1 (2006) S99-S112
17. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 114 (1998) 842-845
18. Shen J., Sakaida I., Uchida K., et al. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci 77 (2005) 1502-1515
19. Sakaida I., Jinhua S., Uchida K., et al. Leptin receptor-deficient Zucker (fa/fa) rat retards the development of pig serum-induced liver fibrosis with Kupffer cell dysfunction. Life Sci 73 (2003) 2491-2501
20. Kitade M., Yoshiji H., Kojima H., et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 44 (2006) 983-991
21. Kaser S., Moschen A., Cayon A., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005) 117-121
22. Kowdley K.V., and Pratt D.S. Adiponectin-tipping the scales from NAFLD to NASH?. Gastroenterology 128 (2005) 511-513 author reply 513
23. Tomita K., Tamiya G., Ando S., et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55 (2006) 415-424
24. Copaci I., Micu L., and Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. J Gastrointestin Liver Dis 15 (2006) 363-373
25. Bertolani C., Sancho-Bru P., Failli P., et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 169 (2006) 2042-2053
26. Jarrar M.H., Baranova A., Collantes R., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 27 (2008) 412-421
27. Hong F., Radaeva S., Pan H.N., et al. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40 (2004) 933-941
28. Schwimmer J.B., Deutsch R., Kahen T., et al. Prevalence of fatty liver in children and adolescents. Pediatrics 118 (2006) 1388-1393
29. Lonardo A., Bellini M., Tartoni P., et al. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 29 (1997) 351-356
30. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
31. Nomura H., Kashiwagi S., Hayashi J., et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 27 (1988) 142-149
32. El-Hassan A.Y., Ibrahim E.M., al-Mulhim F.A., et al. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 65 (1992) 774-778
33. Bedogni G., Miglioli L., Masutti F., et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 46 (2007) 1387-1391
34. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
35. Hilden M., Christoffersen P., Juhl E., et al. Liver histology in a 'normal' population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12 (1977) 593-597
36. Hultcrantz R., Glaumann H., Lindberg G., et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 21 (1986) 109-113
37. Ground K.E. Prevalence of fatty liver in healthy male adults accidentally killed. Aviat Space Environ Med 55 (1984) 59-61
38. Daniel S., Ben-Menachem T., Vasudevan G., et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients.[see comment]. Am J Gastroenterol 94 (1999) 3010-3014
39. Wanless I., and Lentz J. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990) 1106-1110
40. Byron D., and Minuk G.Y. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 24 (1996) 813-815
41. Berasain C., Betes M., Panizo A., et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 47 (2000) 429-435
42. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20 (1989) 594-598
43. Nonomura A., Mizukami Y., Unoura M., et al. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 27 (1992) 521-528
44. Wieckowska A., McCullough A.J., and Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. [review]. Hepatology 46 (2007) 582-589
45. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
46. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 (1995) 1714-1719
47. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 (2004) 750-755
48. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
49. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. [see comment]. Am J Gastroenterol 98 (2003) 2042-2047
50. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. [see comment]. Gastroenterology 129 (2005) 113-121
51. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. [see comment]. J Hepatol 42 (2005) 132-138
52. Charlton M., Kasparova P., Weston S., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7 (2001) 608-614
53. Regimbeau J.M., Colombat M., Mognol P., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transplant 10 Suppl (2004) S69-S73
54. Cotrim H.P., Parana R., Braga E., et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?. Am J Gastroenterol 95 (2000) 3018-3019
55. Zen Y., Katayanagi K., Tsuneyama K., et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51 (2001) 127-131
56. Marrero J.A. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36 (2002) 1349-1354
57. Bullock R.E., Zaitoun A.M., Aithal G.P., et al. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J Hepatol 41 (2004) 685-686
58. Kawada N., Imanaka K., Kawaguchi T., et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 44 (2009) 1190-1194
59. Palekar N.A., Naus R., Larson S.P., et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26 (2006) 151-156
60. Poynard T., Ratziu V., Charlotte F., et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 34
61. Gholam P.M., Flancbaum L., Machan J.T., et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102 (2007) 399-408
62. Mottin C.C., Moretto M., Padoin A.V., et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 14 (2004) 635-637
63. Ryan C.K., Johnson L.A., Germin B.I., et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 8 (2002) 1114-1122
64. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005) E462-E468
65. Sporea I., Sirli R., Deleanu A., et al. Liver stiffness measurement by transient elastography in clinical practice. J Gastrointestin Liver Dis 17 (2008) 395-399
66. Kobayashi A., Kawasaki S., Miyagawa S., et al. Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma. Hepatogastroenterology 53 71 (2006) 736-741
67. Asiyanbola B., Chang D., Gleisner A.L., et al. Operative mortality after hepatic resection: are literature-based rates broadly applicable?. J Gastrointest Surg 12 (2008) 842-851
68. Jarnagin W.R., Gonen M., Fong Y., et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 236 (2002) 397-406 discussion 406-407
69. Iwatsuki S., and Starzl T.E. Personal experience with 411 hepatic resections. Ann Surg 208 (1988) 421-434
70. Imamura H., Seyama Y., Kokudo N., et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 138 (2003) 1198-1206 discussion 1206
71. Hemming A.W., Reed A.I., Fujita S., et al. Role for extending hepatic resection using an aggressive approach to liver surgery. J Am Coll Surg 206 (2008) 870-875 discussion 875-878
72. Finch M.D., Crosbie J.L., Currie E., et al. An 8-year experience of hepatic resection: indications and outcome. Br J Surg 85 (1998) 315-319
73. Belghiti J., Hiramatsu K., Benoist S., et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191 (2000) 38-46
74. Behrns K.E., Tsiotos G.G., DeSouza N.F., et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2 (1998) 292-298
75. Little S.A., Jarnagin W.R., DeMatteo R.P., et al. Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 6 (2002) 88-94
76. Kooby D.A., Fong Y., Suriawinata A., et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7 (2003) 1034-1044
77. McCormack L., Petrowsky H., Jochum W., et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 246 (2007) 940-946 discussion 946-948
78. McCormack L., Petrowsky H., Jochum W., et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 245 (2007) 923-930
79. Barker K.B., Palekar N.A., Bowers S.P., et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 101 (2006) 368-373
80. Liu X., Lazenby A.J., Clements R.H., et al. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 17 (2007) 486-492
81. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
82. Jaskiewicz K., Raczynska S., Rzepko R., et al. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 51 (2006) 21-26
83. Marsman W.A., Wiesner R.H., Rodriguez L., et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 62 (1996) 1246-1251
84. Selzner M., and Clavien P.A. Fatty liver in liver transplantation and surgery. Semin Liver Dis 21 (2001) 105-113
85. Selzner N., Selzner M., Jochum W., et al. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol 44 (2006) 694-701
86. Fishbein T.M., Fiel M.I., Emre S., et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 64 (1997) 248-251
87. Urena M.A., Ruiz-Delgado F.C., Gonzalez E.M., et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc 30 (1998) 3288-3291
88. Adam R., Reynes M., Johann M., et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 23 1 Pt 2 (1991) 1538-1540
89. Urena G.M.A., Colina Ruiz-Delgado F., Moreno Gonzalez E., et al. Hepatic steatosis in liver transplant donors: common feature of donor population?. World J Surg 22 (1998) 837-844
90. Rinella M.E., Alonso E., Rao S., et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 7 (2001) 409-414
91. D'Alessandro A.M., Kalayoglu M., Sollinger H.W., et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 51 (1991) 157-163
92. Ploeg R.J., D'Alessandro A.M., Knechtle S.J., et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 55 (1993) 807-813
93. Yoo H.Y., Molmenti E., and Thuluvath P.J. The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation. Liver Transpl 9 (2003) 72-78
94. Angele M.K., Rentsch M., Hartl W.H., et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg 195 (2008) 214-220
95. Verran D., Kusyk T., Painter D., et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 9 (2003) 500-505
96. Mor E., Klintmalm G.B., Gonwa T.A., et al. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 53 (1992) 383-386
97. Teramoto K., Bowers J.L., Kruskal J.B., et al. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation 56 (1993) 1076-1082
98. Seifalian A.M., Piasecki C., Agarwal A., et al. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 68 (1999) 780-784
99. Hayashi M., Tokunaga Y., Fujita T., et al. The effects of cold preservation on steatotic graft viability in rat liver transplantation. Transplantation 56 (1993) 282-287
100. Seifalian A.M., Chidambaram V., Rolles K., et al. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transpl Surg 4 (1998) 71-77
101. Brandhagen D., Fidler J., and Rosen C. Evaluation of the donor liver for living donor liver transplantation. Liver Transpl 9 Suppl 2 (2003) S16-S28
102. Cho J.Y., Suh K.S., Kwon C.H., et al. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. Surgery 139 (2006) 508-515
103. Yamamoto K., Takada Y., Fujimoto Y., et al. Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation 83 (2007) 257-262
104. Lee J.Y., Kim K.M., Lee S.G., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 47 (2007) 239-244
105. Nair S., Verma S., and Thuluvath P.J. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 35 (2002) 105-109
106. Shields P.L., Tang H., Neuberger J.M., et al. Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 68 (1999) 530-535
107. Carson K., Washington M.K., Treem W.R., et al. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 3 (1997) 174-176
108. Contos M.J., Cales W., Sterling R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 (2001) 363-373
109. Czaja A.J. Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg 3 (1997) 185-186
110. Kim W.R., Poterucha J.J., Porayko M.K., et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 62 (1996) 1802-1805
111. Molloy R.M., Komorowski R., and Varma R.R. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 3 (1997) 177-178
112. Malik S.M., deVera M.E., Fontes P., et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 9 (2009) 782-793
113. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
114. Soejima Y., Shimada M., Suehiro T., et al. Use of steatotic graft in living-donor liver transplantation. Transplantation 76 (2003) 344-348